| ruzinurad (SHR 4640) / Jiangsu Hengrui Pharma |
NCT03015948: A Single Dose Study of SHR4640 in Healthy Male Volunteers |
|
|
| Completed | 1 | 40 | RoW | SHR4640, Placebo | Atridia Pty Ltd. | Gout | 11/16 | 11/16 | | |
NCT02815839: Single Dose Study of SHR4640 in Healthy Subjects |
|
|
| Completed | 1 | 50 | RoW | SHR4640, Placebo | Jiangsu HengRui Medicine Co., Ltd. | Gout; Hyperuricemia | 02/17 | 02/17 | | |
NCT02890966: Multiple Dose Study of SHR4640 in Healthy Subjects |
|
|
| Completed | 1 | 48 | RoW | SHR4640, placebo | Jiangsu HengRui Medicine Co., Ltd. | Gout; Hyperuricemia | 02/17 | 03/17 | | |
NCT03131583: The Drug-Drug Interaction of SHR4640, Febuxostat and Colchicine in Patients With Gout |
|
|
| Completed | 1 | 15 | RoW | Colchicine, Febuxostat, SHR4640 | Jiangsu HengRui Medicine Co., Ltd. | Gout | 01/18 | 01/18 | | |
NCT03211403: Multiple Doses Study of SHR4640 in Male Subjects With High Serum Uric Acid Level |
|
|
| Completed | 1 | 24 | RoW | SHR4640 | Atridia Pty Ltd. | Gout, Hyperuricemia | 02/18 | 02/18 | | |
NCT04260373: Study to Evaluate the Mass Balance and Biotransformation of [14C]SHR4640 in Chinese Healthy Adult Male Volunteers. |
|
|
| Completed | 1 | 6 | RoW | [14C]SHR4640 | Jiangsu HengRui Medicine Co., Ltd. | Healthy Adult Male Volunteers | 04/20 | 04/20 | | |
NCT04157959: The Drug-Drug Interaction of SHR4640 and Febuxostat in Patients With Hyperuricemia |
|
|
| Unknown status | 1 | 28 | RoW | SHR4640 dose1, Febuxostat dose2 | Jiangsu HengRui Medicine Co., Ltd. | Hyperuricemia | 06/20 | 06/20 | | |
NCT04586803: Study on the Bioavailability of Three Different Prescription Processes of SHR4640 Tablets in Healthy Volunteers |
|
|
| Not yet recruiting | 1 | 24 | NA | SHR4640 | Jiangsu HengRui Medicine Co., Ltd. | Primary Gout, Hyperuricemia | 11/20 | 12/20 | | |
NCT04620408: Study on the Food Effects of Oral SHR4640 Tablets in Healthy Volunteers |
|
|
| Not yet recruiting | 1 | 14 | NA | SHR4640 | Jiangsu HengRui Medicine Co., Ltd. | Healthy Subjects | 01/21 | 02/21 | | |
NCT04850638: Drug Interaction Between SHR4640 Tablets and Furosemide Tablets in Healthy Volunteers (Single Center, Single Arm, Open, Self-control) |
|
|
| Completed | 1 | 18 | RoW | SHR4640 tablets and furosemide tablets | Jiangsu HengRui Medicine Co., Ltd. | Healthy Male Subjects | 09/21 | 09/21 | | |
NCT04305392: Pharmacokinetics, Pharmacodynamics and Safety of SHR4640 in Patients With Hepatic Impairment |
|
|
| Active, not recruiting | 1 | 24 | RoW | SHR4640 | Jiangsu HengRui Medicine Co., Ltd. | Hepatic Impairment | 12/22 | 12/22 | | |
NCT05954169: Pharmacokinetic/Pharmacokinetic and Safety Studies of SHR4640 in Subjects With Moderate Renal Insufficiency and Healthy Subjects |
|
|
| Recruiting | 1 | 16 | RoW | SHR4640 | Jiangsu HengRui Medicine Co., Ltd. | Hyperuricemia | 11/23 | 11/23 | | |
NCT06168929: Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy Subjects |
|
|
| Completed | 1 | 34 | RoW | SHR4640 | Jiangsu HengRui Medicine Co., Ltd. | Hyperuricemia | 01/24 | 01/24 | | |
NCT06196580: PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT Interval |
|
|
| Completed | 1 | 24 | RoW | repaglinide; midazolam; SHR4640, repaglinide; midazolam; SHR4640; SHR4640 placebo, repaglinide; midazolam; SHR4640 placebo | Jiangsu HengRui Medicine Co., Ltd. | Gout and Hyperuricemia | 02/24 | 02/24 | | |
